PHAXIAM Therapeutics S.A.

ENXTPA:PHXM Stock Report

Market Cap: €17.2m

PHAXIAM Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PHXM?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders72,1160.72%
Private Companies225,2102.25%
Institutions3,830,47838.3%
General Public5,885,66558.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 64.8%.

Top Shareholders

Top 25 shareholders own 41.13% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
25%
EPIC Bpifrance, Asset Management Arm
2,500,000€4.3m0%5.78%
4.75%
Go Capital SAS
475,606€819.0k1,500%48.18%
4.71%
Tikehau Investment Management SAS
471,777€812.4k0%0.47%
2.05%
Akkadian Partners S.A.
205,695€354.2k0%no data
0.96%
Aviva Investors Global Services Ltd.
95,956€165.2k0%no data
0.54%
SAS Helea Financière
54,375€93.6k0%no data
0.54%
Auriga Partners
54,181€93.3k0%3.14%
0.43%
Rossini Investments S.à R.L.
43,103€74.2k0%no data
0.31%
Valentine Gouedard Comte
31,193€53.7k0%no data
0.26%
Solys
26,189€45.1k0%no data
0.24%
Myropola
24,042€41.4k0%no data
0.17%
Bpifrance Participations SA
17,418€30.0k0%no data
0.16%
MP Deloche & Associates SARL
16,100€27.7k0%no data
0.15%
Paminove
15,376€26.5k0%no data
0.15%
Sc Roc De Lou
15,108€26.0k0%no data
0.14%
Mathieu Bigois
13,700€23.6k0%no data
0.12%
Sofidu
11,854€20.4k0%no data
0.12%
Financiere Saint Romain
11,854€20.4k0%no data
0.09%
Jacques Tcheng
9,016€15.5k0%no data
0.076%
Guy Rigaud
7,576€13.0k0%no data
0.06%
Gestys SA
6,000€10.3k0%0.42%
0.055%
Thibaut Fayet
5,486€9.4k0%no data
0.034%
Friedland Gestion
3,375€5.8k0%0.13%
0.026%
Bernard Linage
2,626€4.5k0%no data
0.01%
Philippe Archinard
1,030€1.8k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PHAXIAM Therapeutics S.A. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mathieu ChabertBryan Garnier & Co
Guillaume CuvillierGilbert Dupont
Martial DescouturesInvest Securities